
usd feb pm et
summari compani lead distributor pharmaceut medical-surg suppli
relat product broad rang health care custom
price-to-earnings oper ep
risk assess reflect benefit
diversifi product servic well strong
long-term growth prospect see drug health
care suppli distributor develop popul age
expand middl class around world gain
access health care also view barrier entri
industri high posit balanc
limit price power especi current
stretch intens drug price pressur vertic
integr medic devic manufactur also
present greater oper litig risk
pure drug distributor view
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
report best quarter revenu
growth two year sep-q yoy
growth led pharma segment
total revenue grew sale yoy
quarter good year pharma
sale growth far ytd sale
yoy vs cy volum
growth largest custom
tailwind specialti
despit strong ytd sale growth
estim ytd adj pre-tax incom
yoy lower profit fuel
poor perform sg grown
yoy sharp drop gross margin
sep-q vs
cite unfavor contract renew
primari culprit declin gross margin
concern margin
pressur
estim
achiev pharma oper margin
roughli bp better averag
competitor lead
shrunk around bp howev due
challeng price pressur key
prospect neutral
share expect margin continu
worsen limit potenti
earn growth view base
on-going consolid health care payer
provid give greater
purchas power well intens
sever gener deflat rang
oper margin pharma segment
declin sinc
yet see sign stabil sep-q
worst margin sinc see
medic segment gener headwind
margin contract well
growth longer tailwind
acquisit patient
recoveri risk view includ
competit larg e-commerc player
contract renew less favor term
target price ep estim
-- discount histor averag
forward price-to-earnings see materi oper
headwind continu well
unresolv litig cordi unit
fiscal year end jun ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic
pharmaceut distribut tradit brand gener drug specialti drug oncolog
infus medic medic manufactur distribut broad rang product
medic glove endovascular stent segment util nation network distribut center
focus medic oper canada europ asia
oper margin gener higher medic fy saw medic oper margin versu
largest custom optumrx pharmaci account roughli
revenu respect five largest custom account revenu distribut
agreement extend june optumrx recent extend june
market profil accord data iqvia hda research foundat pharmaceut sale
reach cy cy pharmaceut sale move
distribut compani cy remaind move directli manufactur
downstream custom within industri sale specialti drug grow faster
tradit drug specialti grew cy tradit contract result
sale mix shift traditional/specialti cy cy
increas access health insur especi global middl class expand age
popul posit driver health care distribut drug price inflat deflat one
critic factor profit return wareh logist inventori data servic
larg distribut contract typic pay distributor negoti percentag purchas order
amount price often negoti manufactur downstream custom rise drug
price therefor lead larger whole dollar servic fee inflat also help distributor tradit
resal arrang purchas bulk inventori manufactur resel
downstream custom see profit rise lower-cost exist inventori sold new higher
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market share
cy addit gener drug sourc joint ventur larg retail
pharmaci becom standard began collabor jv improv
bargain power gener manufactur set similar jv walgreen
respect
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut pharmaceut sale growth slow
respect slower growth tradit drug busi led
distributor seek higher growth margin segment specialti pharmaceut
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti drug busi captur higher growth
margin creat one-stop-shop healthcar provid
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori may patient recoveri acquisit perform accord
plan cordi signific drag earn growth due oper problem inventori
write-down mount litig cost help fuel goodwil impair medic
segment fy
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi acute-car
provid one top two distributor alongsid owen minor barrier entri
industri high due scale capit intens supply-chain infrastructur possess
larg incumb price power extrem limit current environ due custom
consolid polit pressur lower health care cost
price breadth product offer value-ad servic credit term primari competit
factor industri larg multi-year contract consolid amongst downstream custom
major impact distributor earn case lost signific
pharmaci busi merger safeway albertson renew
optumrx contract materi lower margin also medic suppli distribut
agreement kaiser permanent health network incumb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral base mainli
expect tepid growth prescript
drug volum continu
balanc solid growth fda novel drug
approv focu mainli drug
distribut busi compris
sale health care distribut
prescript drug volum seen meager
growth late expect even slower growth
come year estim
year-over-year growth total
toward end think
partli due slow growth
health-insur popul individu
health insur tend fill
prescript without due
lower out-of-pocket drug cost
view expect growth total enrolle
major health insur roughli
flat membership growth often aid
employ ad new hire
company-sponsor health plan robust
job gain may harder come
 economi near full employ
repeal individu mandat
may also begin contribut slower
beyond weak growth prescript volum
deflat gener drug price also
gener headwind distributor earn
case late monthli
year-over-year declin gener drug price
rang
continu sever deflationari trend
expect moder
gener drug deflat next year
howev pace gener approv
slow
histor lower gener approv activ
tend lessen competit gener drug
maker lead price power
expect deflat continu howev
less sever rate due signific price
power garner joint ventur
three major drug distributor three
walgreen
although may
seem counterintuit think power
jv exact price concess
gener maker hurt even drug
distributor apart jv
distributor fee often percentag
sale price trend view
distributor make volum
lost price enter jv
balanc neg see
sub-industri strong fda approv activ
novel drug fda approv new
drug increas
significantli
approv increasd demand driven
new drug potenti signific
tailwind drug distributor come
distributor fell vs rise
fell vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold opinion share cardin inc
lower target price-to-earnings near
low end rang fy jun ep estim
see valuat hurt weak medic segment organ trend unfavor
drug price inflat environ cut fy ep estim
mar-q adjust ep vs estim
neg tax impact weaker cordi result revenu growth line
expect pharmaceut segment sale slightli
expect growth exist custom specialti drug off-set
recent loss prime contract pharmaceut margin
continu pressur low inflat despit improv drug purchas
medic segment sale grew reflect recent acquisit weaker
expect continu challeng cardiolog endovascular
suppli busi cordi see continu fy /joseph agnes
rais target price-to-earnings
near low end rang fy jun ep estim
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi increas fy ep estim
see tax reform increas ep fy
fy dec-q ep vs estim
result benefit strong specialti demand improv purchas /joseph
analyst research note compani news
et cfra maintain hold opinion share inc
keep target fy jun
ep estim -- discount histor forward price-to-earnings averag
expect continu margin contract keep fy ep estim
lower fy dec-q ep vs
ahead consensu driven higher-than-expect revenu dec-q sale
yoy mark three straight quarter impress sale gain
driven higher volum lower sale price rise raw
materi cost continu pressur margin gross margin bp yoy
effici initi appear gain traction though
sg expens yoy overal adjust pre-tax incom flat
yoy per share basi rose reduc share count
yoy aggress repurchas share appear cheap trail
earn continu concern lack price power
et cfra keep hold opinion share cardin inc
rais target ep
estim discount histor averag forward price-to-earnings
signific headwind earn keep fy jun ep
estim lower sept-q ep vs
ahead consensu gener strongest quarter
revenu growth two year yoy estim adjust pre-tax incom
versu prior year period gross margin materi worsen
sg appear rise faster sale gener deflat
pharma segment revenue rise raw materi cost medic
segment drove drop gross margin quarter
year appear cheap trail earn continu
concern path stabil oper earn expect
sever gener deflat continu along rise cost
et cfra lower opinion cardin inc share
hold strong buy drop target
use ev/ebitda multipl materi discount five-year averag
competitor due headwind medic segment target reduc
due lower ebitda forecast drop fy jun ep estim
initi jun-q ep vs beat
consensu below-the-lin item yoy ebitda growth
big miss mainli driven primari pharma segment
expect modest margin declin roughli line competitor yet
bp drop jun-q pharma margin far worst drug
distributor caus lose drug margin lead reduc view
abil navig contract renew maintain earn
previous like valuat saw less-domin medic larger
risk view chang due pharma margin pressur particularli
largest custom must renew fy /colin scarola
style text-align justifi target impli
ev/ebitda multipl ebitda discount five-year
averag multipl competitor reflect issu
medic segment keep jun ep estim lower
ep estim view record-high fda drug approv
potenti driver ep growth support guidanc
cah largest custom health corpor
store retail prescript volum growth think recent
sell-off relat may exagger cnbc
report april would shelv health care distribut effort
due difficulti win sticki hospit custom complex
infrastructur regul drug amzn subsequ june
acquisit mail-ord retail pharmaci neutral view
pharmaci custom drug distributor competitor /colin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
